NovaBridge Biosciences (FRA:0VY)
1.380
-0.020 (-1.43%)
Last updated: Jun 26, 2026, 8:03 AM CET
NovaBridge Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 210.63 | 68.26 | 291.51 | 465.94 | 554.39 |
Short-Term Investments | 0.21 | 105.14 | 20.22 | 34.13 | 118.5 |
Cash & Short-Term Investments | 210.84 | 173.4 | 311.73 | 500.07 | 672.89 |
Cash Growth | 21.59% | -44.38% | -37.66% | -25.68% | -8.24% |
Accounts Receivable | - | - | - | - | 5.2 |
Other Receivables | - | - | - | - | 39.93 |
Total Trade Receivables | - | - | - | - | 45.13 |
Inventory | - | - | - | - | 4.29 |
Other Current Assets | 6.68 | 3.3 | 18.19 | 25.67 | 30.02 |
Total Current Assets | 217.52 | 176.69 | 329.91 | 525.74 | 752.33 |
Net Property, Plant & Equipment | 2.95 | 3.8 | 5.55 | 17.97 | 24.94 |
Other Intangible Assets | - | - | - | 17.24 | 18.83 |
Goodwill | - | - | - | 23.57 | 25.58 |
Long-Term Investments | 37.24 | 30.82 | - | 4.47 | 55.4 |
Other Long-Term Assets | 2.81 | 1.37 | 33.46 | 1.58 | 4.19 |
Total Assets | 260.52 | 212.68 | 368.92 | 590.57 | 881.26 |
Accrued Expenses | 16.82 | 7.53 | 7.85 | 102.43 | 93.35 |
Short-Term Debt | - | - | - | 2.75 | - |
Current Portion of Leases | 0.89 | 0.82 | 0.63 | 3.47 | 4.83 |
Unearned Revenue | - | - | - | 1.26 | - |
Other Current Liabilities | 9.18 | 0.11 | 49.67 | - | - |
Total Current Liabilities | 26.89 | 8.45 | 58.14 | 109.91 | 98.18 |
Long-Term Leases | 2.18 | 3.07 | 3.26 | 4.65 | 12.87 |
Other Long-Term Liabilities | 0.51 | - | 64.93 | 54.15 | 52.84 |
Total Long-Term Liabilities | 2.69 | 3.07 | 68.19 | 58.8 | 65.71 |
Total Liabilities | 29.58 | 11.52 | 126.34 | 168.71 | 163.89 |
Common Stock | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
Treasury Stock | -5.04 | -6.23 | -8.01 | -3.08 | - |
Additional Paid-in Capital | 1,527 | 1,460 | 1,475 | 1,389 | 1,432 |
Accumulated Other Comprehensive Income | 41.55 | 33.38 | 39.77 | 30.99 | -29.34 |
Retained Earnings | -1,332 | -1,286 | -1,264 | -994.82 | -685.16 |
Shareholders' Equity | 230.94 | 201.16 | 242.58 | 421.85 | 717.37 |
Total Liabilities & Equity | 260.52 | 212.68 | 368.92 | 590.57 | 881.26 |
Total Debt | 3.07 | 3.88 | 3.89 | 10.87 | 17.69 |
Net Cash (Debt) | 207.78 | 169.52 | 307.84 | 489.2 | 655.19 |
Net Cash Growth | 22.57% | -44.93% | -37.07% | -25.34% | -10.39% |
Net Cash Per Share | 2.17 | 2.09 | 3.70 | 5.93 | 8.63 |
Book Value | 230.94 | 201.16 | 242.58 | 421.85 | 717.37 |
Book Value Per Share | 2.41 | 2.48 | 2.91 | 5.11 | 9.44 |
Tangible Book Value | 230.94 | 201.16 | 242.58 | 381.05 | 672.97 |
Tangible Book Value Per Share | 2.41 | 2.48 | 2.91 | 4.62 | 8.86 |